Osteotech Bone Grafting Products on Display

Osteotech, Inc., a manufacturer in the emerging field of biologic products for regenerative healing, highlighted three procedure-specific MagniFuse bone-grafting products for different spine therapy areas. To date, MagniFuse has been used in 40 spinal surgeries in the United States, according to the company.

“Our strategy is to utilize our platform technologies to develop procedure-specific products to address critical unmet surgical needs and we are very excited to be highlighting our MagniFuse platform at NASS,” said Sam Owusu-Akyaw, Osteotech’s president and CEO. “By utilizing our MagniFuse product line in posterior cervical, posterolateral and spinal deformity procedures, Osteotech is targeting a significant segment of the spinal therapy area. Feedback from surgeons that have used MagniFuse to date indicates the differentiated characteristics and capabilities supported by our MagniFuse technology have been well received, and we believe we are strongly positioned to become a market leader.”

MagniFuse is a patented, next-generation technology platform that supports a family of high-performance, procedure-specific products that provide for simplified, precision grafting when injury or disease creates a need for bone fusion or new bone growth.

Owusu-Akyaw said the company also would be showcasing its FacetLinx Fusion Technology and Plexur M grafting product.

“Our goal at Osteotech is to continue to commercialize proprietary biologics designed to address the unmet needs of the surgeon community and we believe these introductions illustrate our ability to successfully execute this strategy,” he said. “We are pleased to share them directly with the physician community through NASS this week.”

The three MagniFuse spine products featured at NASS are the PC (posterior cervical), SD (spinal deformity) and PL (posterolateral). Posterior cervical fusion is a surgical procedure to stop motion between two or more vertebrae that may be causing neck pain or damage to the nerves that extend into the upper extremities. Spinal deformities, or curves in the spine, often develop during growth in adolescence or as a result of aging. MagniFuse will be used in the treatment of scoliosis, a frontal spinal deformity where the normal straight alignment of the spine from the front is affected by a curve to the left or right. Posterolateral fusion involves placing bone graft in the posterolateral portion of the spine. This procedure may be recommended as a surgical treatment option for patients with a condition causing spinal instability, such as degenerative disc disease, spondylolisthesis or spinal stenosis, which has not responded to conservative treatment measures (rest, physical therapy or medication).

According to the company, MagniFuse employs a highly active biologic material, derived from an allograft source material containing a higher concentration of multiple natural human growth factors. It is delivered in a unique, resorbable, mesh bag delivery-containment system that is sized specifically for the procedure application, eliminating the graft migration-related issues facing competitive products. It is also radiopaque, enabling surgeons to confirm both intra- and post-operation placement of the graft. The combination of MagniFuse’s formulation and delivery system provides an optimized scaffold comprised of 100 percent bone material that produces targeted bone formation, claims the company’s clinical data supports.

Plexur M is a biocomposite combination of cortical bone fibers and resorbable polymers and may be used in a variety of orthopedic procedures as a bone void filler.

Facet joint disorders are among the most common of all the recurrent, disabling lower back problems that have serious symptoms. FacetLinx is a patent-pending spinal allograft product that treats mechanical and facet-driven back pain by fixating the facet joints or may augment standard instrumented and non-instrumented fusion, offering patients stability “with minimum additional risks,” the company said.

Osteotech, Inc. is headquartered in Eatontown, N. J.